Specialty Pharmacy

Study examines how bacteria in the digestive tract might increase or decrease response to cancer drugs.

Sheila Arquette, RPh, director of Pharmacy Services at Independent Health, discusses how specialty pharmacists can help patients manage adverse events from their treatment regimen.

The World Health Organization recently announced plans to launch a pilot program for prequalifying biosimilars.

Top news of the day from across the health care landscape.

Chronic hepatitis B virus is still a problem in many parts of the world and the United States, despite the availability of a vaccine.

Top news of the week in oncology and cancer drug development.

A robust data reporting infrastructure would greatly benefit specialty pharmacy stakeholders.

Laquinimod fails to outperform placebo in patients with relapsing-remitting MS.

Top news of the day from across the health care landscape.

Top articles of the week on Specialty Pharmacy Times.

Keytruda improved overall response rate and progression free survival in NSCLC.

HIV has become a chronic disease that requires a different strategy with aging patients.

Findings highlight the need for continuous safety monitoring of novel therapeutics.

The cost of branded, specialty, and generic drugs increased 8.77% in 2016.

Health care use before an initial demyelinating event suggests a measureable prodromal period in multiple sclerosis.

Top news of the day from across the health care landscape.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies help advance the goals of accountable care organizations.

Patients diagnosed with colorectal cancer are at a higher risk for mood disorders such as depression, bipolar disorder, and anxiety.

Altered stem cells are capable of developing into cartilage cells that create a biologic anti-inflammatory drug.

The use of specialty drugs for weight loss, building muscle mass, or for cosmetic purposes carries risky implications.

New data provides insight into the safety and efficacy of the FDA-approved multiple sclerosis drug.

The study is the first to demonstrate that CRISPR/Cas9 technology may lead to an HIV cure.

Top news of the day from across the health care landscape.

Scott Gottlieb has served as the FDA Deputy Commissioner under President George W. Bush, a senior advisor to the FDA commissioner, and as FDA Director of Medical Policy Development.

Avelumab (Bavenico) approved for advanced or metastatic urothelial carcinoma.

Substantial proportion of patients with ulcerative colitis or Crohn’s disease achieved mucosal healing with vedolizumab.

MedChew Rx is a cannabidiol that treats pain and spasticity associated with multiple sclerosis.